← Evidence library

BIB_394

McKechnie et al. 2024 Melanoma Res — statins & melanoma survival meta-analysis: non-significant 13% 5-yr OS benefit point estimate (HR 0.87, 95% CI 0.73–1.04), very-low certainty. Parallels BIB393 (GLP-1): a CV-indicated drug is NOT melanoma-adverse → strengthens the brief's "CV/metabolic optimisation is the dominant lever AND melanoma-safe" spine.

Evidence grade

C

Tier

1 (Melanoma Research, peer-reviewed meta-analysis; abstract-level — Wolters Kluw

Cited by tasks

12, 25

Identifiers

DOI:10.1097/CMR · PMID:39264579

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_394/findings.md (research corpus). This page is a short context summary — not individualised medical advice.